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Case Report Rapport de cas
Severe pruritus and myoclonus following intrathecal morphine 
administration in a dog
Isabelle Iff, Karin Valeskini, Martina Mosing
Abstract — During epidural needle placement in a 32-kg dog the subarachnoid space was punctured and half the 
intended dose of lidocaine, bupivacaine, and morphine was injected. After recovery from anesthesia the dog showed 
signs of severe pruritus of the tail base and limbs and myoclonus of the tail and hind limbs. Methadone, aceproma-
zine, ketamine, buprenorphine, and butorphanol were administered to control myoclonus and pruritus, but were 
unsuccessful. Diazepam was used to control myoclonus until the effects of morphine abated.
Résumé — CHECK FOR FRENCH TITLE  
 
 
 
 
(Traduit par Isabelle Vallières)
Can Vet J 2012;53:0000–0000
I ntrathecal injection is not commonly performed as a local anesthetic technique in dogs, whereas epidural anesthesia is a 
widely used and an effective method of providing perioperative 
and postoperative analgesia. Inadvertent subarachnoid punc-
ture occurs in 2% to 4% of cases during epidural anesthesia in 
small animals (1,2) and, if this occurs, a 50% reduction of the 
intended epidural dose is recommended (3,4).
Epidural local anesthetics provide profound intraoperative 
analgesia and are often combined with longer lasting agents 
such as morphine (4). Epidural morphine provides prolonged 
segmental analgesia during the post-operative period with mini-
mal systemic side effects (4). Pruritus and myoclonus are rarely 
observed side effects of neuraxial anesthesia in dogs. Pruritus 
has been described in 0.8% of dogs administered epidural 
morphine and/or bupivacaine (5). Side effects are more com-
monly observed after intrathecal opioid administration than 
after epidural injection (3,4). Myoclonus has been reported 
in 3 dogs following intrathecal administration of morphine in 
doses ranging from 0.15 to 2.3 mg/kg (6–8).
This case report describes the treatment of pruritus and 
myoclonus in a dog after subarachnoid administration of a 
combination of lidocaine, bupivacaine, and morphine.
Case description
A 6-year-old spayed female mixed breed dog, weighing 32 kg 
was scheduled for a tibial plateau levelling osteotomy. Pre-
anesthetic medication consisted of acepromazine (Vanastress; 
Vana GmbH, Vienna, Austria), 0.02 mg/kg body weight 
(BW) and methadone (Heptadon; EBEWE Pharma GesmbH, 
Unterach, Austria), 0.1 mg/kg BW, intravenously (IV). 
Anesthesia was induced with propofol IV to effect (Propofol-
Fresenius; FreseniusKabi GmbH, Bad Homburg, Germany) 
(total dose 4 mg/kg BW). The trachea was intubated and the 
endotracheal tube connected to an anesthetic circle system. 
Anesthesia was maintained with isoflurane (Isoflo, Abbot) 
in 100% oxygen, and an epidural injection of lidocaine 
(Xylanaestpurum 2%; Gebro Pharma GmbH, Fieberbrunn, 
Austria), bupivacaine (Carbostesin 0.5%; AstraZeneca GmbH, 
Wedel, Germany), and morphine (10 mg/mL, Vendal, 
Lannacher Heilmittel, Lannach, Austria) was planned as part 
of a balanced anesthetic protocol. All drugs for epidural injec-
tion were drawn from previously unused vials and the dog was 
positioned in sternal recumbency with the hind legs extended 
cranially. The skin over the lumbosacral space was clipped and 
aseptically prepared and a 20-G spinal needle (Yale; Becton 
Dickinson, Fraklin Lakes, Neww Jersey, USA) was inserted until 
a “pop” was felt when penetrating the ligamentum flavum. Free 
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flow of cerebrospinal fluid (CSF) was observed on removal of 
the stylet indicating subarachnoid puncture. As a result, half 
of the intended volume was injected, resulting in a total dose 
of 0.05 mg/kg BW preservative-free morphine, 0.62 mg/kg 
BW lidocaine, and 0.31 mg/kg BW bupivacaine (total volume 
3.16 mL). Anesthesia lasted 3 h and was uneventful with all 
measured cardiovascular and respiratory parameters within 
physiologic ranges. Lactated Ringer’s solution was infused at 
10 mL/kg BW per hour throughout the procedure.
The dog started to lick and bite bilaterally at the base of the 
tail region about 15 min after extubation. The dog was awake 
and responsive, but had not regained motor function of her 
pelvic limbs. Palpation of the wound did not elicit a reaction; 
however, in response to tactile stimulation at the base of the tail 
violent biting of the region was elicited. As the dog became more 
alert, the licking increased in severity and occasional twitches 
of the tail were observed (about every 10 s). Acepromazine 
0.02 mg/kg BW was administered IV as the dog became 
distressed after excluding a distended bladder or the need for 
defecation by abdominal palpation. Additionally, methadone, 
0.1 mg/kg BW, IV and then ketamine (Ketasol Narketan10%; 
Vétoquinol Austria GmbH, Vienna, Austria), 0.5 mg/kg BW, IM 
were given to ensure sufficient analgesia. There was a decrease 
in licking, but not in muscular twitches, which became more 
severe over the 3 h following extubation. Rhythmic twitching 
(1 twitch per 10 s) affected the whole caudal half of the body 
and this progressed to clusters of approximately 10 twitches 
(1 per second) every 15 to 20 s, leading to a diagnosis of myoc-
lonus. The dog became increasingly agitated and diazepam 
(Valium; Roche Austria GmbH, Vienna, Austria), 1 mg/kg BW 
was administered IV. Heavy sedation resulted and the frequency 
and intensity of myoclonus decreased. However, an additional 
injection of 0.5 mg/kg BW diazepam was necessary after 
15 min due to recurrence of severe and frequent myoclonus. 
Buprenorphine (Temgesic; AESCA GesmbH, Traiskirchen, 
Austria), 0.01 mg/kg BW and butorphanol (Butomidor, Richter 
Pharma AG, Wels, Austria), 0.2 mg/kg BW were given IV 2 h 
and 3 h after extubation, respectively, with the intention of 
partially reversing the actions of morphine at the mu (MOP) 
receptor. Both agents proved to be ineffective in eliminating 
pruritus and myoclonus completely; however, signs of distress 
were not evident. The dog slowly recovered from sedation and 
5 h after extubation showed infrequent episodes of pruritus 
(every 5 or 6 min) and less frequent myoclonus (1 twitch every 
30 to 40 s). Frequency and severity of myoclonus and pruritus 
decreased further over time. At about 8 h after extubation they 
were only visible after tactile stimulation of the sacral region. All 
symptoms ceased about 10 h after extubation. The dog urinated 
normally at this time. Clinical examination performed the fol-
lowing day was unremarkable and the dog was discharged. The 
dog was lost to follow-up.
Discussion
This report describes pruritus and myoclonus after spinal 
anesthesia. One reason for an adverse drug reaction such as 
this is the use of preservatives in neuraxially administered solu-
tions. None of the drugs used contained preservatives and the 
data sheets of all agents indicate their suitability for neuraxial 
use in humans. Another reason for an adverse drug reaction is 
interaction between components of the injectate. Mixing local 
anesthetics and opioids is common practice to achieve excel-
lent intraoperative analgesia (local anesthetic) combined with 
prolonged postoperative pain relief (opioid). Neural blockade 
produced by mixing local anesthetics is deemed unpredictable 
and controversial and depends on a number of factors (9). In 
this case, lidocaine and bupivacaine were mixed based on the 
perceived advantage of combining agents to achieve a quick 
onset and long duration of action (10). Retrospectively, the 
physicochemical properties (color, formation of precipitate, pH, 
specific gravity) of the individual solutions and of the mixture 
were assessed in a new set of bottles (Table 1). Lidocaine and 
bupivacaine are stable in pH 6 to 7, if used soon after mixing 
(9). Other authors have stated that the consideration from pH 
changes may be unimportant when used for single administra-
tion since the buffering capacity in the body is sufficient to 
increase the pH of the anesthetic solution into the physiologic 
range (11). We assume that pruritus and myoclonus were a side 
effect of spinal anesthesia rather than from a physicochemical 
change due to mixing the drugs. Initial treatment of pruritus 
and myoclonus utilized conventional therapy: tranquilizers 
(acepromazine and diazepam), opioids (methadone, buprenor-
phine, and butorphanol), and an N-methyl-D-aspartate receptor 
antagonist (ketamine). These treatments were met with varying 
success and the waning effect of morphine over time is consid-
ered the main reason for improvement.
The occurrence of pruritus after neuraxial anesthesia was 
reported in 2/242 dogs (0.8%) after epidural morphine with 
or without bupivacaine (5). However, the publication does not 
detail if the dogs with pruritus received only morphine or both 
agents (5). Pruritus following intrathecal injection of morphine 
(0.1 mg/kg BW) with preservatives has been reported in sheep 
with 2/37 animals (5.4%) affected (12). In human patients 
receiving epidural or intrathecal opioids the incidence of pru-
ritus has been reported as 8.5% and 46%, respectively (13). 
Pruritus in the dog described here was so severe that intervention 
was necessary as the dog became distressed while trying to lick 
and chew the affected area. Self-mutilation of the tail and pelvic 
limbs has been described after spinal morphine administration 
in dogs (3). As well as the unpleasant sensation of pruritus, the 
dog started to show myoclonus, which progressed over the first 
3 h after extubation. Myoclonus after epidural morphine injec-
tion has been reported to be very rare (4). Two case reports of 
myoclonus in dogs after intrathecal morphine injection can be 
found in the literature. These dogs received 3 times and 30 times 
the intrathecal dose of preservative-free morphine reported here 
Table 1. Physicochemical properties of lidocaine, bupivacaine and 
a lidocaine-bupivacaine mixture
Agent pH SG Precipitate Color
lidocaine 2% 6.2 1.015 no clear
bupivacaine 0.5% 5.0 1.008 no clear
lidocaine 2%-bupivacaine 0.5%  5.5 1.011 no clear 
 mixture (1:2)
SG — specific gravity.
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(6,7). Both dogs had to be managed with general anesthesia in 
order to control myoclonus; therefore, it is impossible to say if 
pruritus was present in these dogs.
This is the first description of a dog suffering from both 
pruritus and myoclonus after intrathecal injection of a com-
monly used dose of preservative-free morphine. Considering the 
pathophysiology of each of the symptoms it becomes evident 
that several mechanisms have to be involved. Itch is an unpleas-
ant sensation stemming probably from afferent C fibers with 
excessive terminal branching eliciting a reflex or desire to scratch 
(14). With neuraxial administration peripheral mechanisms, like 
histamine release, causing itch are less likely (14). Several central 
mechanisms are proposed in the literature to be responsible 
for itching after administration of opioids; however, the exact 
mechanisms remain unclear. Opioid receptors in the superficial 
and deep dorsal horn neurons may be involved in signalling this 
sensation. It has been hypothesized that opioids are directly and 
indirectly involved in the facilitation of protective reflexes and 
itch and hyperalgesia are the manifestation of this. Pruritus 
may be caused by a facilitation of superficial neuronal response 
to histamine coupled with inhibition of deep dorsal horn neu-
rons with intrathecal morphine administration (13). However, 
other receptors in the spinal cord or brain that may be involved 
include dopamine D2 receptors, 5-HT3 receptors, prostaglan-
din system, as well as GABA, and/or glycine receptors (14). In 
animals, similarities between hyperalgesia induced by intrathecal 
opioids and by glycine antagonism have been described (13). 
In animals this hyperalgesia syndrome is not abolished by nal-
oxone, contrary to the findings in humans in whom naloxone 
sometimes can reduce hyperalgesia and itch (13).
The pathophysiologic mechanism of myoclonus is not 
known. Studies in animals and spinal neuronal cultures have led 
to various theories explaining muscular hyperactivity: an interac-
tion of morphine with non-opioid (GABA and glycine) receptors 
in the central nervous system, potentially blocking the postsyn-
aptic inhibition (13); activation of spinal serotonergic systems 
causing myoclonic activity following high doses of intrathecal 
morphine (15); or indirect activation of N-methyl-D-aspartate 
receptors (has been implicated in causing myoclonus, but this 
has been questioned) (16). Evidence that non-opioid receptors 
are likely to be involved in the occurrence of myoclonus is that 
symptoms cannot be treated with naloxone (13,16).
The treatment of the dog herein followed the main recom-
mendations found in the literature. When only pruritus was 
evident, we administered acepromazine as an emergence reaction 
from anesthesia was assumed and the duration of action is 6 to 
8 h. Distress due to a distended bladder or the need to defecate 
with incomplete motor control was ruled out by abdominal 
palpation. Severe acute pain causing licking and biting as a 
form of self-mutilation was a differential diagnosis to pruritus; 
however, several factors make this interpretation unlikely. There 
was minimal motor control of the hind limbs on recovery, 
indicating residual action of the local anesthetics, and minimal 
change of the symptoms with the administration of methadone 
and ketamine, making the sensation of pain unlikely. At this 
time the dog was responsive to its environment and it became 
obvious that the dog suffered from severe pruritus.
No clear guidelines exist for treatment of opioid-induced 
pruritus. For small animals, suggested treatment options include 
systemic antihistamines such as diphenhydramine and MOP 
receptor antagonists such as butorphanol, nalbuphine, and 
naloxone as well as acepromazine to eliminate anxiety until the 
epidural opioids have worn off (3). Acepromazine may have an 
additional benefit, as it acts on central dopamine and 5-HT3 
receptors. As histamine release has been implicated to play a role 
by some authors, treatment with H1 and H2 blockers might 
be warranted (17). However, other authors questioned their 
usefulness and antihistaminic agents were not administered in 
this case (14).
Butorphanol [kappa (KOP) agonist- MOP antagonist] is 
effective in attenuating neuraxial morphine-induced itch with-
out reducing morphine analgesia in primates (18). The use of 
buprenorphine, a partial MOP agonist for the treatment of 
non-opioid induced pruritus is described in humans (19). In 
the present study, butorphanol and buprenorphine were used 
in an attempt to reduce itching while maintaining an acceptable 
analgesic level after major surgery. Buprenorphine was given 
as it has a long duration of action; when, after 1 h no effect 
was obvious butorphanol was considered as the next option. 
However, neither butorphanol nor buprenorphine administra-
tion decreased the severity of pruritus in this case. Naloxone was 
not administered as a first line of treatment for ethical reasons, 
as inadequate analgesia might have resulted and the treatment 
with a KOP agonist- MOP antagonist may have been more 
suitable (19). The severity of the signs decreased and the dog 
was not distressed by the time the effects of buprenorphine and 
butorphanol were evaluated and administration of naloxone 
was not deemed necessary. Naloxone is effective in preventing 
or treating intrathecal or epidural opioid-induced itching in 
humans (13). However, there is some indication that naloxone 
may not be as useful in abolishing pruritus in animals as in 
humans (13).
The literature was subsequently reviewed and alternative 
treatment options specifically for the treatment of opioid 
induced pruritus have been identified. Propofol depresses pos-
terior horn transmission in the spinal cord, possibly reducing 
itching (14). It has been used at subanesthetic doses to treat 
opioid-induced pruritus; however, mixed results have been 
reported (19). Another therapeutic option would have been 
ondansetron, which resulted in variable results ranging from 
helpful to ineffective in humans (19). Dopamine D2 receptor 
antagonists (reduced intensity only) and droperidol have been 
used successfully in the treatment of opioid-induced pruritus 
in humans (19).
In the dog reported here, myoclonus occurred after recovery 
about 3 h after intrathecal injection, starting at the tail. Onset 
of generalized myoclonus after administration of 2.3 mg/kg 
BW morphine injected into the cisternal space is described 
after 15 min in an awake dog, resulting in death 50 min after 
administration (8). This report mentions that myoclonus starts 
in the pelvic limbs when morphine is administered in the 
lumbar intrathecal space (8). Other reports in anesthetized 
animals describe onset times of 50 and 90 min after lumbar 
intrathecal injection of 1.3 and 0.15 mg/kg BW of morphine, 
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respectively (6,7). Two of the reports also describe worsening 
of signs with mechanical or tactile stimulation, similar to our 
description (7,8). Various treatment approaches for myoclonus 
have been described. Variable effects have been reported with 
the systemic or epidural administration of benzodiazepines 
and baclofen (6,7). The administration of diazepam brought 
temporary relief in the dog reported here and an additional 
dose had to be given, as the effect seemed short lasting. The 
dog was also heavily sedated and by the time the dog recovered 
it seemed to be less distressed; therefore, further administration 
of benzodiazepines did not seem necessary. Benzodiazepines 
were also initially effective in the treatment of myoclonus in 
2 aforementioned case reports in dogs (6,7).
Another option is the use of non-depolarizing muscle relax-
ants in anesthetized animals. Variable success has been reported 
with the use of atracurium in dogs (6,7). As the use of non-
depolarizing muscle relaxants makes unconsciousness and 
intermittent positive pressure ventilation necessary we did not 
consider their use in the first instance. Pentobarbital was eventu-
ally used to control the myoclonus in one of the aforementioned 
dogs, while in the dog with the intrathecal morphine overdose 
it was ineffective (6,7). Pentobarbital was not necessary, but 
was discussed as the next treatment option in the dog reported 
here. As discussed previously, intravenous naloxone shows little 
effect on myoclonus after epidural or systemic injection as the 
pathophysiologic mechanism is not opioid receptor related.
Local anesthetics have been suggested to reduce opioid-
induced myoclonus (21). One possible explanation for the 
relatively late onset of myoclonus compared with the other cases 
reported may be that intrathecal local anesthetics were admin-
istered together with morphine in our case (6–8). However, a 
recent case report has suggested intrathecal bupivacaine as the 
cause of myoclonus (21). Alternatively, the late appearance of 
myoclonus in our case might be due to the fact that ketamine, 
an N-methyl-D-aspartate receptor antagonist, was injected 
when pruritus became evident in order to achieve better non-
opioid related analgesia. The administration of an N-methyl-
D-aspartate receptor blocker might have delayed the appearance 
of myoclonus in relation to the pruritus. Indeed ketamine has 
been used to prevent morphine-induced hind limb myoclonic 
seizures in mice (22).
The time course and duration of side effects in the canine 
reports is very variable and in the dog reported here myoclo-
nus and pruritus were absent at 13 h after intrathecal injec-
tion. Myoclonus was absent 9 and 22 h after administration 
of morphine in the 2 surviving dogs previously reported, 
although no earlier attempts to wean them off their respective 
treatment protocols had been made (6,7). The duration of side 
effects may depend on the duration of action of intrathecal 
morphine as well as the amount administered. Experimentally 
0.01 to 0.04 mg/kg BW of intrathecal morphine provided an 
antinociceptive effect for 8 h, at which time data acquisition 
was terminated (23). Clinically, intrathecal use of morphine is 
mainly reported when puncturing the dura with a failed epidural 
approach. Current dose recommendations are 0.05 mg/kg BW 
for inadvertent dural puncture and 0.03 mg/kg BW for canine 
spinal surgery patients (3,4,24).
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